<DOC>
	<DOC>NCT00424892</DOC>
	<brief_summary>The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.</brief_summary>
	<brief_title>Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome</brief_title>
	<detailed_description>Patients completing study 3151A4-327 have the opportunity to be treated with DVS SR during the 6 month extension study.</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Outpatients who have completed doubleblind treatment in study 3151A4327 for fibromyalgia Syndrome with no major protocol violations and no events that would preclude the patient's entry into the longterm openlabel study. Women of childbearing potential must have a negative serum pregnancy test result at study start. Exclusion criteria: Presence of any new/and or clinically important medical condition that might compromise patient's safety. Use of prohibited treatment. Meets any of the exclusion criteria listed for study 3151A4327.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>